Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 75 years old, inclusive.~* Patient has a diagnosis of RA according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for at least 6 months~* Patient has active disease as defined by the presence of 6 or more swollen joints (of 28 assessed), 6 or more tender joints (of 28 assessed) and serum C-reactive protein (CRP) concentration \>0.6 mg/dL~* Patient who completed at least 3 months of treatment of oral or parenteral dosing with Methotrexate between 12.5 to 25 mg/kg (between 10 to 25 mg/week in Korea) and on stable dosing with Methotrexate for at least 4 weeks prior to the first administration of the study drug.~Exclusion Criteria:~* Patient who has previously received a biological agent for the treatment of RA and/or a TNFα inhibitor for the treatment of other disease~* Patient who has allergies to any of the excipients of infliximab or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product~* Patient who had current or past history of chronic infection with hepatitis C or human immunodeficiency virus (HIV)-1 or -2 or current infection with hepatitis B~* Patient who had acute infection requiring oral antibiotics within 2 weeks or parenteral injection of antibiotics within 4 weeks prior to the first administration of the study drug, other serious infection within 6 months prior to the first administration of study drug or recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug.~* Patient who had an indeterminate result for interferon-γ release assay (IGRA) or latent tuberculosis (TB) at Screening. For Part 2, if IGRA result was indeterminate at Screening, 1 retest was possible during the screening. If the repeated IGRA result was negative, the patient could be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: CT-P13 IV 3 mg/kg (Type: ACTIVE_COMPARATOR): CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
- Cohort 2: CT-P13 SC 90 mg (Type: EXPERIMENTAL): CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
- Cohort 3: CT-P13 SC 120 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
- Cohort 4: CT-P13 SC 180 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
- Arm 1: CT-P13 SC 120 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
- Arm 2: CT-P13 IV 3 mg/kg (Type: ACTIVE_COMPARATOR): CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).